MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.

IF 2.2 4区 医学 Q3 ONCOLOGY Oncology Letters Pub Date : 2018-05-01 Epub Date: 2018-03-19 DOI:10.3892/ol.2018.8294
Wei Tang, Weiguang Wang, Yuchi Zhao, Zhongyuan Zhao
{"title":"MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.","authors":"Wei Tang, Weiguang Wang, Yuchi Zhao, Zhongyuan Zhao","doi":"10.3892/ol.2018.8294","DOIUrl":null,"url":null,"abstract":"MicroRNAs (miRNAs) perform important roles in the development and progression of human malignancy. miR-874, as a tumor suppressor, is decreased in malignant tumors, including osteosarcoma. However, the potential mechanism of miR-874 in osteosarcoma remains largely unknown. In the present study, a dual-luciferase reporter system supported cyclin-dependent kinase 9 (CDK9) as a direct target gene of miR-874. miR-874 mimics evidently repressed CDK9 expression in osteosarcoma. Furthermore, osteosarcoma tissues and cell lines exhibited increased expression of CDK9, and CDK9 expression levels were inversely correlated (R=−0.725) with that of miR-874 in osteosarcoma tissues. Finally, CDK9 overexpression reversed the potential effect of miR-874 on the proliferation and invasion of osteosarcoma cells. Overall, the results revealed that miR-874, as a tumor suppressor, is involved in osteosarcoma progression and metastasis by targeting CDK9, indicating that the miR-874/CDK9 pathway may serve as a potential therapeutic target for the treatment of osteosarcoma.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":" ","pages":"7649-7654"},"PeriodicalIF":2.2000,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3892/ol.2018.8294","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ol.2018.8294","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/3/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 16

Abstract

MicroRNAs (miRNAs) perform important roles in the development and progression of human malignancy. miR-874, as a tumor suppressor, is decreased in malignant tumors, including osteosarcoma. However, the potential mechanism of miR-874 in osteosarcoma remains largely unknown. In the present study, a dual-luciferase reporter system supported cyclin-dependent kinase 9 (CDK9) as a direct target gene of miR-874. miR-874 mimics evidently repressed CDK9 expression in osteosarcoma. Furthermore, osteosarcoma tissues and cell lines exhibited increased expression of CDK9, and CDK9 expression levels were inversely correlated (R=−0.725) with that of miR-874 in osteosarcoma tissues. Finally, CDK9 overexpression reversed the potential effect of miR-874 on the proliferation and invasion of osteosarcoma cells. Overall, the results revealed that miR-874, as a tumor suppressor, is involved in osteosarcoma progression and metastasis by targeting CDK9, indicating that the miR-874/CDK9 pathway may serve as a potential therapeutic target for the treatment of osteosarcoma.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MicroRNA-874通过靶向细胞周期蛋白依赖性激酶9抑制骨肉瘤细胞增殖和侵袭。
MicroRNAs (miRNAs)在人类恶性肿瘤的发生和发展中发挥着重要作用。miR-874作为肿瘤抑制因子,在包括骨肉瘤在内的恶性肿瘤中降低。然而,miR-874在骨肉瘤中的潜在机制在很大程度上仍然未知。在本研究中,双荧光素酶报告系统支持细胞周期蛋白依赖性激酶9 (CDK9)作为miR-874的直接靶基因。miR-874模拟物明显抑制骨肉瘤中CDK9的表达。此外,骨肉瘤组织和细胞系中CDK9表达增加,且在骨肉瘤组织中CDK9表达水平与miR-874表达水平呈负相关(R=-0.725)。最后,CDK9过表达逆转了miR-874对骨肉瘤细胞增殖和侵袭的潜在影响。总之,结果显示miR-874作为一种肿瘤抑制因子,通过靶向CDK9参与骨肉瘤的进展和转移,这表明miR-874/CDK9通路可能作为骨肉瘤治疗的潜在治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Letters
Oncology Letters ONCOLOGY-
CiteScore
5.70
自引率
0.00%
发文量
412
审稿时长
2.0 months
期刊介绍: Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease. The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
期刊最新文献
Erratum: [Corrigendum] Targeted silencing of CXCR4 inhibits epithelial-mesenchymal transition in oral squamous cell carcinoma. Epstein-Barr virus+ inflammatory follicular dendritic cell sarcoma with clonal immunoglobulin heavy chain gene rearrangement: A case report and literature review. [Retracted] Knockdown of lncRNA NUTM2A-AS1 inhibits lung adenocarcinoma cell viability by regulating the miR-590-5p/METTL3 axis. Primary bone marrow diffuse large B-cell lymphoma with secondary myelofibrosis: A case report. Tanshinone IIA targets RNF123 to inhibit non-small cell lung cancer cell proliferation, migration and invasion via KAT2B-mediated H3K18ac modification.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1